| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 706 | 2009 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... J Clin Oncol 27 (16), 2622-2629, 2009 | 506 | 2009 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 379 | 2007 |
| High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 305 | 2008 |
| Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ... European journal of cancer 44 (13), 1875-1882, 2008 | 258 | 2008 |
| Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition GS Wong, J Zhou, JB Liu, Z Wu, X Xu, T Li, D Xu, SE Schumacher, ... Nature medicine 24 (7), 968-977, 2018 | 232 | 2018 |
| Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer F Graziano, N Galluccio, P Lorenzini, A Ruzzo, E Canestrari, S D'Emidio, ... J Clin Oncol 29 (36), 4789-4795, 2011 | 204 | 2011 |
| Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ... J Clin Oncol 24 (12), 1883-1891, 2006 | 196 | 2006 |
| Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer F Graziano, A Ruzzo, F Loupakis, E Canestrari, D Santini, V Catalano, ... Journal of Clinical Oncology 26 (9), 1427-1434, 2008 | 153 | 2008 |
| Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes D Santini, S Angeletti, A Ruzzo, G Dicuonzo, S Galluzzo, B Vincenzi, ... Clinical & Experimental Immunology 154 (3), 360-364, 2008 | 139 | 2008 |
| Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer F Graziano, F Arduini, A Ruzzo, I Bearzi, B Humar, H More, R Silva, ... Clinical Cancer Research 10 (8), 2784-2789, 2004 | 136 | 2004 |
| Genetic modulation of the let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ... The pharmacogenomics journal 10 (5), 458-464, 2010 | 133 | 2010 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy A Ruzzo, F Graziano, F Loupakis, D Santini, V Catalano, R Bisonni, ... The pharmacogenomics journal 8 (4), 278-288, 2008 | 129 | 2008 |
| Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer B Humar, F Graziano, S Cascinu, V Catalano, AM Ruzzo, M Magnani, ... Oncogene 21 (53), 8192-8195, 2002 | 128 | 2002 |
| Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer F Graziano, A Ruzzo, E Giacomini, T Ricciardi, G Aprile, F Loupakis, ... The pharmacogenomics journal 17 (3), 258-264, 2017 | 108 | 2017 |
| Identification of seven novel germline mutations in the human E‐cadherin (CDH1) Gene H More, B Humar, W Weber, R Ward, A Christian, C Lintott, F Graziano, ... Human mutation 28 (2), 203-203, 2007 | 98 | 2007 |
| Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype A Ruzzo, F Graziano, F Pizzagalli, D Santini, V Battistelli, S Panunzi, ... Annals of oncology 16 (6), 887-892, 2005 | 97 | 2005 |
| High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory … A Ruzzo, F Graziano, B Vincenzi, E Canestrari, G Perrone, N Galluccio, ... The oncologist 17 (6), 823-829, 2012 | 96 | 2012 |
| Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy K Kawakami, F Graziano, G Watanabe, A Ruzzo, D Santini, V Catalano, ... Clinical cancer research 11 (10), 3778-3783, 2005 | 91 | 2005 |
| Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population F Graziano, K Kawakami, A Ruzzo, G Watanabe, D Santini, F Pizzagalli, ... International journal of cancer 118 (3), 628-632, 2006 | 89 | 2006 |
Mauro MagnaniProfessor of BiochemsitryVerified email at uniurb.it
